

## **Bio Behavioral Health joins PhaseWell Research to Expand Access to Neuropsychiatric Clinical Trials**

*The Bio Behavioral Health acquisition strengthens PhaseWell's national footprint and advances community-based research in central nervous system (CNS) therapeutic areas.*

**NASHVILLE, Tenn.** — PhaseWell Research (“PhaseWell”), a national clinical research site company, today announced a new partnership with Bio Behavioral Health (“BBH”), a leading central nervous system (CNS) research site focused in neurologic and psychiatric disorders. The partnership reflects PhaseWell’s continued commitment to connecting communities to clinical trials, bringing hope today and shaping tomorrow’s medicine.

Headquartered in Nashville, Tennessee, PhaseWell Research is focused on increasing participation in clinical trials by enabling research within trusted, high-performing sites and community practices nationwide. The addition of Bio Behavioral Health further strengthens PhaseWell’s growing network and enhances its capabilities in neurologic and psychiatric research – areas of increasing clinical and societal need.

Based in Toms River, New Jersey, Bio Behavioral Health brings deep expertise in conducting clinical trials in the community setting, with a strong emphasis on patient-centered care, rigorous data quality, and efficient study execution. Through this partnership, PhaseWell and BBH will expand access to clinical research opportunities for patients while supporting sponsors with reliable enrollment, operational excellence, and high-integrity data.

“Partnering with Bio Behavioral Health aligns perfectly with our mission to expand access to complex clinical research in the community setting,” said Carsten Bick, Chief Executive Officer of PhaseWell Research. “Neuropsychiatric disorders represent a critical and growing area of unmet need in the United States, but the medical science coming down the pike is potentially game-changing for this patient population. By combining PhaseWell’s national platform with BBH’s expertise and community reach within the therapeutic area, we are improving our position to increase patient access to this incredibly important next generation of therapeutics.”

The partnership builds on PhaseWell’s foundation of trusted research organizations with longstanding reputations for excellence across complex therapeutic areas. With more than 1,800 clinical trials completed and contributions to the approval of over 150 therapies, PhaseWell delivers comprehensive Phase I–IV clinical trial services across oncology, CNS, cardiovascular/metabolic, and dermatology.

“Joining PhaseWell Research allows us to scale our impact while staying true to our mission of delivering compassionate, community-based neuropsychiatric research,” said Dr. Ashok Patel, founder and leading principal investigator at Bio Behavioral Health.

“Together, we can broaden access to clinical trials for patients, strengthen partnerships with sponsors and CROs, and continue advancing high-quality research that meaningfully contributes to the advancement of medicine in our space.”

To learn more about PhaseWell Research, please visit [www.phasewell.com](http://www.phasewell.com) or contact [info@phasewell.com](mailto:info@phasewell.com).

### **About PhaseWell Research**

PhaseWell Research is a clinical research site company united by a shared commitment to connecting our communities to clinical trials, bringing hope today and shaping tomorrow’s medicine. With a national network of high-performing sites, PhaseWell delivers comprehensive Phase I-IV clinical trial services across a broad range of therapeutic areas, including oncology, central nervous system (CNS), cardiovascular/metabolic, dermatology, and behavioral health. PhaseWell’s physicians and investigators are recognized industry leaders known for their clinical expertise and operational excellence. By leveraging proven recruitment strategies and deep access to diverse patient populations through robust databases and strategic partnerships, PhaseWell has successfully completed more than 1,800 clinical trials and contributed to the approval of over 150 therapies. To learn more, visit [www.phasewell.com](http://www.phasewell.com).

### **About Bio Behavioral Health**

Led by Dr. Ashok Patel, Bio Behavioral Health is a community-based CNS clinical research site headquartered in Toms River, New Jersey. Since its founding in 1987, Bio Behavioral Health has advanced mental and behavioral health care by conducting more than 200 clinical trials. The organization partners closely with patients, healthcare providers, and study sponsors to deliver patient-centric research across a broad range of behavioral health and CNS indications, including, but not limited to, depression, bipolar disorder, ADHD, Alzheimer’s disease, Parkinson’s disease, schizophrenia, post-traumatic stress disorder, and anxiety. Bio Behavioral Health is widely recognized for its commitment to ethical research practices, strong patient engagement, and the reliable execution of clinical studies within real-world clinical settings.

### **Contacts**

[info@phasewell.com](mailto:info@phasewell.com)